Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Predictors of drug survival of biologic therapies in psoriasis patients
By
- AMS
posted
May 13, 2020 02:18 PM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study
- AMS
Added Jan 12, 2021
Blog Entry
Real world use of biologic drug levels and anti-drug antibodies in patients with psoriasis – does therapeutic drug monitoring have a place in routine clinical practice?
- AMS
Added Mar 15, 2021
Blog Entry
Increased biologic utilization in Latino patients with psoriasis
- AMS
Added Jul 20, 2020
Blog Entry
Epidemiology of moderate-to-severe psoriasis: a comparison between psoriasis patients treated with biological agents, conventional systemic drugs and topical agents
- AMS
Added Oct 21, 2020
Blog Entry
Deferred time of delivery of biologic therapies in patients with stabilized psoriasis leads to a ‘perceived satisfaction’: a multicentric study
- AMS
Added Apr 29, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic